Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Gilead's $29bn buy arrives

Posted 23 December 2020 AM

A first-in-class breast cancer immunotherapy recently acquired by Gilead has made its first appearance in Australia with the TGA granting the drug a priority review determination.

Trodelvy is a Trop-2 directed antibody-drug conjugate which the company added to its oncology pipeline when it bought Immunomedics in October for approximately US$21 billion (AU$29 billion).

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pitfalls may plague NMP review
With an election in play, will it arrive too late?
Approvals Action
First copy of Halaven ticked
Along with other generics of already PBS-listed drugs